Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.44 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855945 | 0.90 | SOAT2 (0.47) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL855709 | 0.90 | SOAT2 (0.50) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL855984 | 0.89 | SOAT2 (0.47) | NR1H4SOAT2ACAT1SOAT1UBE2M | |
| SCHEMBL855316 | 0.87 | SOAT2 (0.44) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL854758 | 0.85 | SOAT2 (0.47) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL854439 | 0.85 | SOAT2 (0.47) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL856560 | 0.85 | SMN1; SMN2 (0.46) | SOAT2SOAT1SMN1; SMN2UBE2MDCUN1D1 | |
| SCHEMBL856052 | 0.84 | SOAT2 (0.46) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL854639 | 0.84 | SOAT2 (0.46) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 | |
| SCHEMBL855915 | 0.84 | SOAT2 (0.46) | NR1H4SOAT2ACAT1SOAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308438-B9 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-1308438-B1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7105567-B2 | 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308438-A1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | NR1H4 141/4885SOAT2 3181/4885ACAT1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.